Press Releases


The Edith Sanford Breast Foundation is committed to building a library of news and information relating to our research and efforts to find cures faster, keeping our promise to freely share our breast cancer research with the world.

Contact us for additional information or to schedule an interview.

Sanford among 14 organizations working with IBM to advance cancer genomics

IBM Watson Health aims to accelerate personalized treatment options, cut DNA analysis time NEW YORK – IBM Watson Health is partnering with more than a dozen leading cancer institutes,
IBM Watson Health aims to accelerate personalized treatment options, cut DNA analysis time
NEW YORK - IBM Watson Health is partnering with more than a dozen leading cancer institutes, including Sanford Health, to quickly translate DNA insights into personalized treatment options for patients. The project is part of IBM’s broader Watson Health initiative to advance patient-centered care and improve health.
Across its enterprise, Sanford will utilize Watson Genomic Analytics, a cloud-based service for evidence gathering and analysis. It looks for variations in the full human genome and uses Watson’s cognitive capabilities to examine all available data sources such as treatment guidelines, research, clinical studies, journal articles and patient information. Watson Genomic Analytics then provides a list of relevant medical literature and drugs. The patient's doctor reviews this information alongside underlying evidence to make more informed treatment decisions. Watson Genomic Analytics constantly gets smarter as the system learns from patient data.
The collaborations will enable clinicians to use Watson with a much broader set of patients by the end of 2015, and will accelerate the promise of personalized medicine for cancer patients everywhere.
“Customized cancer treatment based on a tumor’s genetic composition is the future of cancer therapy,” said Steven Powell, M.D., a Sanford Health oncologist and cancer researcher based in Sioux Falls, South Dakota. “However, due to the unique genetic make-up of each individual and the complexities of the cancer genome, a personalized approach can take an enormous amount of time to process. For any type of disease, rapid analysis and understanding of this complex genomic information will lead to more precise and effective treatments.”
Read the rest of the press release on sanfordhealth.org.

Edith Sanford Breast Foundation named Reebok Spartan Race Charity Partner

  SIOUX FALLS, S.D. – The Edith Sanford Breast Foundation announced today that it will be the official charity partner of the 2015 SoCal Reebok Spartan Race in Vail Lake, Calif., Sept.
  SIOUX FALLS, S.D. – The Edith Sanford Breast Foundation announced today that it will be the official charity partner of the 2015 SoCal Reebok Spartan Race in Vail Lake, Calif., Sept. 26-27.
The Foundation invites athletes to race with its national charity team, TeamEdith, and compete while raising funds and awareness for the mission to end breast cancer. Every dollar raised will advance cutting-edge genomics research.
Edith Sanford’s goodwill ambassador and TeamEdith captain, Thad Beaty, guitarist for Grammy Award-winning band Sugarland, will compete with TeamEdith on race day and train with members online in advance.
“Like Edith Sanford, the Reebok Spartan Race is committed to empowering women and men of all ages to embrace fitness as a lifestyle that can transform your health and well-being,” said Beaty. “We’re honored to team up with Spartan and challenge athletes to do something huge for themselves and for the fight to end breast cancer.”
Reebok Spartan Race is the fastest growing series in the sport of obstacle racing. The SoCal race will feature both a Spartan Sprint, 3+ miles with 20+ obstacles, and a Spartan Beast, 13+ miles with 30+ obstacles, which will test participants mentally and physically.
“We are thrilled to partner with the Edith Sanford Breast Foundation for our SoCal race to help raise awareness for their mission to end breast cancer,” said Joe De Sena, Founder and CEO of Spartan Race. “We are moved by the Foundation’s mission to invest every dollar raised to help find cures faster. We look forward to TeamEdith completing our rugged mountain race packed with obstacles to excite and challenge the already accomplished national charity team.”
Registration for the SoCal Sprint and Beast is open now. TeamEdith race bibs for the Spartan Sprint are available for a $250 donation to the Edith Sanford Breast Foundation. Members who join will also be eligible for VIP perks on race day. Details are available at edithsanford.org/teamedith.

About Reebok Spartan Race


  Founded in 2010, Reebok Spartan Race is defining the Sport of Spartan Racing and is the global leader in the sport of obstacle racing. Reebok Spartan Race caters to individuals looking to test their physical limits and change their frame of reference for what they can accomplish, from everyday people looking to get off the couch and lead a more fit lifestyle, to elite endurance athletes who seek the ultimate physical test. Currently, Reebok Spartan Race offers four primary race formats, "Spartan Kids" (1/2 Mile/1 Mile), “Spartan Sprint” (3+ miles; 20+ obstacles), “Spartan Super” (8+ miles; 25+ obstacles) and “Spartan Beast” (13+ miles; 30+ obstacles), along with additional events that cater to more seasoned athletes.
Reebok Spartan Race is a timed event, making it a true sport with global athlete rankings, event winners and a World Championship event. Competitors are encouraged to complete each of the primary adult race distances to achieve “Spartan TRIFECTA” status. With over 50 races slated for the United States in 2015 and an additional 70+ races scheduled across 20 countries internationally, Reebok Spartan Race urges you to change your life today by signing up to race at www.spartan.com.

Edith Sanford Breast Foundation announces Thad Beaty of Sugarland to be new goodwill ambassador

SIOUX FALLS, S.D. – The Edith Sanford Breast Foundation today welcomed musician Thad Beaty as its newest goodwill ambassador in the fight to end breast cancer. Beaty, guitarist for the Grammy
SIOUX FALLS, S.D. – The Edith Sanford Breast Foundation today welcomed musician Thad Beaty as its newest goodwill ambassador in the fight to end breast cancer. Beaty, guitarist for the Grammy Award-winning band Sugarland and an accomplished athlete and fitness expert, will help promote health and wellness as part of Edith Sanford’s focus on breast cancer risk reduction.
As a triathlete, marathon competitor and certified running and triathlon coach, Beaty will play a key role in leading TeamEdith, the Foundation’s national fundraising team. He will engage with TeamEdith members online, sharing training and healthy lifestyle tips, and participate in TeamEdith events nationwide.
After years of struggling to make his own health a priority while touring as a musician, Beaty says his mother’s cancer diagnosis in 2009 was a wake-up call. Through exercise and diet changes, he lost 70 pounds during an 18-month period and found a calling to help others get and stay healthy while giving back.
“Living your full potential is about more than physical health; it’s emotional and spiritual. It’s finding balance and contributing to something bigger than yourself,” said Beaty. “I’m excited to lead TeamEdith in support of Edith Sanford, and help inspire and challenge others to see how much they can achieve for themselves, and for the fight against breast cancer.”
TeamEdith, which is free to join, allows women and men of all ages to support the Edith Sanford Breast Foundation while achieving their own health and fitness goals. Every dollar raised is directly invested in breast cancer research to help find the cures.
Beaty’s inaugural race with TeamEdith will be June 13, 2015, at the Rock ‘n’ Roll Seattle Marathon and ½ Marathon in Seattle, Washington, where Edith Sanford will be featured as the event’s official charity partner. Registration is now open. To learn more about TeamEdith and view upcoming events, visit edithsanford.org/teamedith.
“The Edith Sanford Breast Foundation found its perfect match in Thad,” said Christine Dockter, the Foundation’s chief development officer. “Not only does he have the fitness expertise and experience to inspire others toward more healthy, risk-reducing lifestyle habits, his enthusiasm for raising awareness and funds for the cause is contagious.”

About the Edith Sanford Breast Foundation


The Edith Sanford Breast Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. To learn more, please visit edithsanford.org.

Edith Sanford Breast Foundation Named Official Charity of Rock ‘n’ Roll Denver

Partnership aims to generate awareness and support fundraising to end breast cancer for future generations through genomics research. Rock ‘n’ Roll Denver Marathon & 1/2 Marathon to take

  • Partnership aims to generate awareness and support fundraising to end breast cancer for future generations through genomics research.
  • Rock ‘n’ Roll Denver Marathon & 1/2 Marathon to take place Sunday, October 18.
  • Sugarland’s Thad Beaty announced as Edith Sanford Breast Foundation’s Goodwill Ambassador.
DENVER — June 2, 2015 — The Edith Sanford Breast Foundation, a national non-profit advancing research to end breast cancer, has been named as the official charity of the Rock ‘n’ Roll Denver Marathon & 1/2 Marathon. The event will take place the weekend of October 18.
“The Edith Sanford Breast Foundation is thrilled to be the official charity of this incredible race,” said Christine Dockter, chief development officer of the Foundation. “We welcome all runners to race and rock out with TeamEdith in Denver to help make a real and lasting impact in the fight to end breast cancer.”
The Edith Sanford Breast Foundation is committed to advancing genomics research to accelerate breakthroughs in the personalized prevention, early detection and treatment of breast cancer. By joining TeamEdith, runners can support the Edith Sanford Breast Foundation’s bold approach to breast cancer through their event training and race participation. The Foundation dedicates 100 percent of every dollar raised to research that will help save lives today and protect future generations from the pain and suffering of breast cancer.
The Edith Sanford Breast Foundation recently announced Thad Beaty from the Grammy award-winning band Sugarland as the organization’s goodwill ambassador. Beaty is a triathlete, marathon finisher and certified running and triathlon coach. He will play a key role in the Foundation’s fundraising and will participate in events nationwide.
“We are proud to support this wonderful organization as they seek to find cures for breast cancer,” said Dave Hussa, Vice President of Charity Partnerships. “We encourage runners to make their miles more impactful by participating with TeamEdith at Rock ‘n’ Roll Denver.”
The Rock ‘n’ Roll Series is known for placing entertainment stages along the race course, lining the route with local cheerleaders and then topping the experience off with a finish line concert celebration for all participants. The musically themed races have spearheaded an active lifestyle movement that provides a unique entertainment outlet for people from all walks of life.
Over the 18-year history of the Rock 'n' Roll Marathon Series, charity participants have raised more than $310 million for a variety of worthy causes and nonprofit organizations. For more information on the Rock ‘n’ Roll Marathon Series, visit RunRocknRoll.com or follow @RunRocknRoll on Twitter.

About Rock ‘n’ Roll Denver


A Competitor Group Inc. event, the 6th annual Rock ‘n’ Roll Denver Marathon & ½ Marathon will take place on Sunday, October 18, 2015. Live bands and cheerleaders will entertain participants along every mile of the scenic course, which starts near the State Capitol in downtown Denver and travels past many of the city’s major landmarks and parks. The race concludes with a finish line festival at Civic Center Park and post-race concert. A two-day Health & Fitness Expo kicks off race weekend on Friday, October 16 and Saturday, October 17. The free expo is open to the public and will feature the latest in running apparel and nutrition products. For more information, or to register online, please visit RunRocknRoll.com.

About the Edith Sanford Breast Foundation


The Edith Sanford Breast Foundation supports a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. To learn more, visit edithsanford.org.
###
Media Contact: Amana Miyamae amiyamae228@gmail.com 970-402-0390
Dan Cruz dcruz@competitorgroup.com 619-925-7671

Edith Sanford Breast Foundation Named Official Charity of Rock ‘n’ Roll Seattle Marathon

Partnership aims to generate awareness and support fundraising to end breast cancer for future generations through genomics research. SEATTLE – April 10, 2015 – The Rock ‘n’ Roll Marathon Series

Headsweats Becomes the Official Headwear and Corporate Partner of the Edith Sanford Breast Foundation

  Cincinnati, OH – March 6, 2015 – Headsweats headwear, the world leader in performance headwear for athletes, is thrilled to announce its most recent partnership with the Edith Sanford

 

Headsweats

Cincinnati, OH – March 6, 2015 – Headsweats headwear, the world leader in performance headwear for athletes, is thrilled to announce its most recent partnership with the Edith Sanford Breast Foundation, an organization committed to conducting groundbreaking research to find a cure faster.


"The Edith Sanford Breast Foundation is proud to join forces with an innovative, like-minded partner like Headsweats, whose team shares our passion for finding a cure for Breast Cancer," Christine Dockter, Chief Development Officer of the Edith Sanford Breast Foundation, said. "Together, we will help speed up research to end this devastating disease and inspire more people to invest in their health through active, risk-reductive lifestyles."


Edith Sanford Breast Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations. To encourage people to stay healthy and fit, the foundation started TeamEdith, a combination of half marathons, marathons and triathlons held throughout the US. TeamEdith directs 100% of funds raised to advance breast cancer research.


“Headsweats is happy to partner with and support the Edith Sanford Breast Foundation in their search for the cure,” Alan Romick, Owner and Founder of Headsweats, said. “Not only are they conducting invaluable research in the fight against this disease, but they are also encouraging people to stay healthy and take steps towards prevention as well, something Headsweats stands behind completely.”


Headsweats headwear will be available through the TeamEdith program. For more information on the Edith Sanford Breast Foundation or to find out how you can help, visit www.edithsanford.org. To learn more about Headsweats, go to www.headsweats.com or email Angie Houck at angie@darbycommunications.com.


About Headsweats


Headsweats is the leader in ultra-light, supremely wicking performance headwear that dominates the triathlon, cycling, running and endurance markets. For over 15 years, Headsweats has established itself as the frontrunner in technical headwear by combining the spirit of innovation, unsurpassed customer service and well-developed partnerships with high profile events and brands such as Tour de France, US Military Endurance Sports, Loudmouth and Challenged Athletes Foundation. With a dedication to seeking out and using innovative materials and designs, Headsweats makes the highest quality headwear in the industry. Keep a cool head. www.headsweats.com

Edith Sanford Breast Foundation named official charity partner of 2016 Little Debbie IRONMAN Chattanooga Triathlon presented by McKee Foods

SIOUX FALLS, S.D./TAMPA, Fla. – The Edith Sanford Breast Foundation has been named the official charity partner of the Little Debbie IRONMAN® Chattanooga triathlon presented by McKee Foods on

SIOUX FALLS, S.D./TAMPA, Fla. – The Edith Sanford Breast Foundation has been named the official charity partner of the Little Debbie IRONMAN® Chattanooga triathlon presented by McKee Foods on Sept. 25, 2016. The Foundation invites athletes to race with its national charity team, TeamEdith, and compete while raising funds and awareness for the mission to end breast cancer.

“We’re honored to team up with IRONMAN and challenge athletes to make their 140.6 miles on race day even more meaningful,” said Micah Aberson, president of the Edith Sanford Breast Foundation. “Every dollar raised by TeamEdith competitors will help advance cutting-edge breast cancer research to find cures and raise the standard of breast care for women everywhere.”

While general entry to the race is sold out, there are a limited number of guaranteed spots available on TeamEdith for a commitment to raise at least $3,500 for the Edith Sanford Breast Foundation. In addition to the pride of making a difference in the fight to end breast cancer, TeamEdith members will enjoy additional benefits, including priority placement of bicycle racks, access to a team hospitality tent, exclusive training and nutrition tips, and more. Athletes already registered for the race can learn how to join TeamEdith and enjoy the benefits by visiting their website.

“IRONMAN is honored to partner with TeamEdith and help make a difference in the fight against breast cancer,” said Dave Deschenes, executive director of The IRONMAN Foundation. “Men and women alike are impacted by breast cancer, and we are glad that through this race and our athletes, there is an opportunity to support TeamEdith’s mission.”

Edith Sanford’s goodwill ambassador, TeamEdith captain, and IRONMAN Certified Coach Thad Beaty, guitarist for Grammy Award-winning band, Sugarland, will also lead activities on race day and train with members online in advance.

“TeamEdith athletes push the limits, physically and emotionally, to make a difference in the fight to end breast cancer,” said Beaty. “IRONMAN triathlon is a powerful platform for these inspiring men and women to bring their passion for the sport and the cause.”

For more information on joining TeamEdith please visit: www.edithsanford.org/teamedith/ironman-chattanooga

For more information on the IRONMAN brand and global event series, visit www.ironman.com.

About the Edith Sanford Breast Foundation

The Edith Sanford Breast Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. To learn more, please visit edithsanford.org.

About IRONMAN

The iconic IRONMAN® Series of events is the largest participation sports platform in the world. Since the inception of the IRONMAN® brand in 1978, athletes have proven that ANYTHING IS POSSIBLE® by crossing finish lines at the world’s most challenging endurance races. Recognized for excellence through distinguished events, world-class athletes and quality products, IRONMAN has grown from a single race to a global sensation with more than 250 events and five unique brands: IRONMAN®, IRONMAN® 70.3®, 5150™ Triathlon Series, Iron Girl ® and IRONKIDS®. For more information, visit www.ironman.com.

###

Tim Gerszewski

Sanford Media Strategist

605-366-2432 / timothy.gerszewski@sanfordhealth.org

@SanfordTimG

Ellie Seifert

IRONMAN Director of Public Relations

516-993-6449 / ellie.seifert@ironman.com / press@ironman.com

Edith Sanford Breast Foundation named Spartan Race charity partner

Funds raised support genomics research SIOUX FALLS, S.D. – The Edith Sanford Breast Foundation announced today that it will be the official charity partner of the 2016 Nashville Reebok Spartan Funds raised support genomics research SIOUX FALLS, S.D. – The Edith Sanford Breast Foundation announced today that it will be the official charity partner of the 2016 Nashville Reebok Spartan Sprint at Fort Campbell on Aug. 20. The Foundation invites athletes to race with its national charity team, TeamEdith, and compete while raising funds and awareness for the mission to end breast cancer. Every dollar raised will advance cutting-edge genomics research.Spartan Edith Sanford’s goodwill ambassador and TeamEdith captain, Thad Beaty, guitarist for Grammy Award-winning band Sugarland, will train with members online in advance. Beaty, along with his wife and fellow musician, Annie Clements, both Nashville locals, will also compete with TeamEdith on race day. “Edith Sanford is honored to team up with Spartan Race and challenge athletes to do something huge for themselves and for the fight to end breast cancer,” said Micah Aberson, president of the Edith Sanford Breast Foundation. “We share Spartan’s commitment to inspiring and empowering women and men of all ages to embrace fitness as a lifestyle.” Spartan Race is the world’s leading obstacle race company. The Nashville Spartan Sprint will feature a distance of three to five miles with more than 20 obstacles to test participants mentally and physically. “We are thrilled to partner with the Edith Sanford Breast Foundation for our Nashville race to help raise awareness for their mission to end breast cancer,” said Ian Lawson, vice president of sponsorship at Spartan Race. “We are moved by the Foundation’s mission to invest every dollar raised to help find cures faster. We look forward to TeamEdith completing our rugged race packed with obstacles to excite and challenge the already accomplished national charity team.” Registration for the Nashville Spartan Sprint is open now. TeamEdith race bibs are available for a $150 donation to the Edith Sanford Breast Foundation. Members who join will also be eligible for VIP perks on race day. Details are available at edithsanford.org/teamedith.   About the Edith Sanford Breast Foundation The Edith Sanford Breast Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. To learn more, please visit edithsanford.org.   About Spartan Race Spartan Race is the world’s leading obstacle race company and the first of its kind to feature timing and global rankings. With more than 170 events in 25+ countries planned for 2016, Spartan Race has more than 1 million global participants, and offers open heats for all fitness levels as well as competitive and elite heats. With nearly 5 million passionate social media followers, health and wellness products, as well as the popular NBC television series, Spartan Race has made obstacle racing one of the fastest growing sports—and lifestyles— in the world. Spartan Race features races at three distances, 3+Mile/20+ Obstacle “Sprint,” 8+ Mile/25+ Obstacle “Super” and 12+ Mile/30+ Obstacle “Beast,” culminating each year in the Reebok Spartan Race World Championship. Visit http://www.spartan.com for more information, a schedule of events, and to register for a race.

Edith Sanford Welcomes National Genomic Oncology Advisor

Stanford University oncologist, geneticist named to position with Edith Sanford Breast Cancer team (Sioux Falls, SD) –A leading medical oncologist and geneticist at Stanford University has

Stanford University oncologist, geneticist named to position with Edith Sanford Breast Cancer team

Ford(Sioux Falls, SD) –A leading medical oncologist and geneticist at Stanford University has joined the Edith Sanford Breast Cancer team as its national genomic oncology advisor. James Ford, MD, will guide the organization on clinical research and personalized treatments for breast cancer. As Edith Sanford’s national genomic oncology advisor, Dr. Ford will help develop and launch clinical trials in genomics and provide technical expertise to treating physicians based on the interpretation of genomic data gathered from those clinical trials. “Dr. Ford is devoted to studying the genetic basis of breast cancer development, treatment and prevention,” said Gene Hoyme, MD, president of Sanford Research and chief academic officer. “His research vision supports that of Edith Sanford, which is to understand the role of genetic variances in cancer genes in regard to the risk and development of breast cancer and other common cancers.” Dr. Ford is currently an associate professor of medicine (oncology) and genetics and director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at Stanford University Medical Center. He graduated from Yale University in 1984 and received his medical degree from the Yale School of Medicine in 1989. The recipient of numerous national awards, Dr. Ford is also an editor for Cancer Research, PLoS Genetics and DNA Repair and serves on the scientific review committee for the V Foundation for Cancer Research.   About Sanford Health and Edith Sanford Breast Cancer Sanford Health is the largest rural nonprofit health care system in the nation with locations in 126 communities, in nine states. In addition, this dynamic integrated health system is now developing international clinics in Ghana, Israel and Mexico. Sanford Health has more than 26,000 employees, and includes 39 hospitals, 140 clinic locations and 1,360 physicians in 81 specialty areas of medicine. In 2011, Sanford Health announced the launch of the Edith Sanford Breast Cancer initiative, a bold new endeavor to end breast cancer, comprised of state-of-the-art patient care, genomic research and national fundraising through the Edith Sanford Breast Cancer Foundation. For more information, visit sanfordhealth.org or edithsanford.org.

Edith Sanford Breast Cancer, Athena Breast Health Network Team for Breast Cancer Research; AKESOgen to Perform Analysis

Genetic analysis of 3,000 women could identify cancer risk Three thousand biospecimens from women will be analyzed as part of the ongoing collaboration between Edith Sanford Breast Cancer and Genetic analysis of 3,000 women could identify cancer risk Three thousand biospecimens from women will be analyzed as part of the ongoing collaboration between Edith Sanford Breast Cancer and Athena Breast Health Network to determine whether certain genetic variants could be indicators of breast cancer, officials from both organizations announced today. The effort aims to gather information that will impact prevention strategies and more precisely identify risk levels of developing breast cancer. As part of the study, 1,500 women at elevated risk and 1,500 women at average risk for breast cancer will be genotyped. “We believe this to be one of the largest groups of women to ever be studied to determine breast cancer risk levels,” said Gene Hoyme, MD, president of Sanford Research. “If an elevated risk is identified, care teams can improve the likelihood of healthier lifestyle changes and implement preventative treatments when appropriate.” In November, Edith Sanford Breast Cancer and Athena Breast Health Network announced a partnership in which Sanford Health became a clinical partner with the Athena Breast Health Network, positioning the health system to begin providing patients with a comprehensive breast cancer risk assessment at the time of mammography screening. Additionally, the program will offer patients the opportunity to participate in research aimed at gaining a better understanding of breast cancer and its risk factors, ultimately raising the standard of care for women everywhere. To analyze each sample from the 3,000 women, AKESOgen, an Atlanta-based biomarker and genetics company selected by Edith Sanford and Athena, will utilize Oncochip technology. “The Oncochip is a uniquely designed genetic analysis tool that uses Illumina’s beadarray technology. It will allow us to provide genetic data of the highest quality to the collaboration. The data will benefit both the participants and the breast cancer research community,” said Mark Bouzyk, PhD, chief scientific officer of AKESOgen. Data gathered and studied by Edith Sanford and Athena could positively influence the risk-assessment tool and care plans. “The addition of the genetic variants risk assessment allows us to deliver a new level of personalized medicine and gain a better understanding an individual’s risk, thus putting our collaboration at the forefront of modern medicine,” said Laura van ‘t Veer, PhD, Director of Applied Genomics at the University of California, San Francisco and an Athena spokesperson. Athena Breast Health Network is a collaboration among the five University of California medical centers. Edith Sanford Breast Cancer is its first partner outside of California and was selected because of its expertise in breast cancer genomics and its ability to integrate the risk assessment into patient care.   About Sanford Health and Edith Sanford Breast Cancer Sanford Health is the largest rural nonprofit health care system in the nation with locations in 126 communities, in nine states. In addition, this dynamic integrated health system is now developing international clinics in Ghana, Israel and Mexico. Sanford Health has more than 26,000 employees, and includes 39 hospitals, 140 clinic locations and 1,360 physicians in 81 specialty areas of medicine. In 2011, Sanford Health announced the launch of the Edith Sanford Breast Cancer Initiative, a bold new endeavor to end breast cancer, comprised of state-of-the-art patient care, genomic research and national fundraising through the Edith Sanford Breast Cancer Foundation. For more information, visit sanfordhealth.org or edithsanford.org. About Athena Breast Care Network The Athena Breast Health Network (Athena) is a unique collaboration among the five University of California (UC) medical/cancer centers (UC Davis, UC Irvine, UCLA, UC San Diego and UCSF), the Graduate School of Public Health at UC Berkeley, and many other public and private partners. The Network takes a transdisciplinary approach by design, and its participants work together across fields including: epidemiology, genetics, molecular biology, psychology and social and behavioral sciences, primary care, radiology, pathology, oncology, surgery and health services research. Also included are clinical staff and genetic counselors, health information technology professionals, health care administrators, and importantly, patient advocates. Athena is integrating clinical care and research in order to revolutionize the delivery of breast care. By standardizing the collection of data from both patients and physicians, integrating molecular profiling at the time of breast cancer diagnosis, and creating an unparalleled biospecimen repository, Athena will enable personalized care informed by science and will fuel continuous improvement in treatment options and outcomes. Key components of Athena include: • Identifying women at high risk for breast cancer who will be offered prevention services and decision support • A comprehensive informatics strategy that includes tools to collect, analyze, and distribute clinical and research data in real time • Web-based decision tools for patients and providers to translate clinical evidence into actionable treatment options – allowing physicians to tailor treatment to biology, patient preference and clinical performance • A data and biospecimen repository to support large-scale, longitudinal studies that will enable tailored prevention and treatment strategies Underpinning these goals is a culture that supports continuous improvement, as well as a commitment by Athena clinicians and researchers across California to share data. With this unique collaboration, Athena aims to change the options for patients today and create a better future for all women at risk of developing breast cancer. UC Disclaimer The information stated above was prepared by Sanford Health and reflects solely the opinion of the health system. Nothing in this statement shall be construed to imply any support or endorsement of Sanford, or any of its products, by The Regents of the University of California, its officers, agents and employees. About AKESOgen, Inc. AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com. ###

Sanford Health Announces $125M Gift to Fund Genomic Initiative

Denny Sanford’s gift launches Sanford Imagenetics (Sioux Falls, SD) – Sanford Health announced today Denny Sanford, the preeminent health care philanthropist in the United States, will

Denny Sanford’s gift launches Sanford Imagenetics

(Sioux Falls, SD) - Sanford Health announced today Denny Sanford, the preeminent health care philanthropist in the United States, will gift the organization $125 million to establish Sanford Imagenetics, a first-of-its-kind program in the country that integrates genomic medicine into primary care for adults. “Mr. Sanford’s generosity to this organization is humbling,” said Kelby Krabbenhoft, president and CEO of Sanford Health. “Including this $125 million gift, Denny has given Sanford Health nearly a billion dollars. It’s an incredible honor as well as a tremendous responsibility.” Internal medicine physicians assist adult patients by diagnosing and managing complex health issues. Later this year, Sanford Imagenetics will offer patients the opportunity to undergo precise genetic testing and genetic counseling, which will provide internal medicine physicians with unprecedented patient-specific information. Arming these physicians with their patients’ genetic information will improve their ability to prescribe the right medication, appropriate dose or most effective treatment with drugs such as statins and blood thinners. “Most physicians can only dream of what it would be like to practice not only on the cutting edge of medical advancement but also working to fundamentally change how patients are treated. The creation of this environment does not occur spontaneously. It requires great leadership and generosity at a level not previously seen,” said Eric Larson, MD, board-certified internal medicine physician with Sanford Health. Sanford Health has a long-standing history of providing comprehensive genetic health care to the region. With Sanford Imagenetics, Sanford’s MD geneticists, genetic counselors and diagnostic clinical genetics laboratories will move hand in hand with the organization’s internal medicine physicians. There are currently no organizations in the country that similarly embed genetics health care professionals into these primary care practices. “Thanks to Mr. Sanford’s continued generosity, Sanford Health will take a national lead role in using existing genetic markers and incorporating future discoveries for internists to individualize care for patients with cancer, diabetes, hypertension, coronary artery disease and other conditions,” said Dan Blue, MD, president of Sanford Clinic. Sanford Imagenetics will include development of a rigorous research program to define the genomic markers most successful in managing primary care for adults. It will also complement the genomics research underway through Edith Sanford Breast Cancer, another initiative founded through Denny Sanford’s generosity, which is pursuing individualized prevention and treatment strategies for breast cancer. “We will also study the outcomes to evaluate the efficacy of this approach as well as in-depth bioinformatics research focused on the practical clinical interpretation of the complicated biological data,” said Gene Hoyme, MD, president of Sanford Research and board certified geneticist. As a part of this initiative, Sanford Health will also have dedicated facilities in all major markets to accommodate implementation of this new program throughout the enterprise.  Depending on the region, these facilities would house the internal medicine practice, genetic counselors, medical geneticists, research, education, and lab services. Sanford Health has already begun recruiting the best and brightest in the fields of internal medicine and genetics to support Sanford Imagenetics. Additionally, Sanford Imagenetics has developed initial partnerships with Augustana College and the University of South Dakota to develop new academic programs that train the next generation of doctors, nurses and scientists in genomic medicine. Learn more at sanfordhealth.org/imagenetics.   About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation. It is the largest rural, nonprofit health care system in the nation with locations in 126 communities, in nine states.   About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations.    

Edith Sanford Research Team to Present at 2013 San Antonio Breast Cancer Symposium

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation today released a schedule detailing research that will be presented by Edith Sanford Breast Cancer Research leaders at the 2013 (Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation today released a schedule detailing research that will be presented by Edith Sanford Breast Cancer Research leaders at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium next week. The conference will run from December 10 – 14, in San Antonio, Texas. Brian Leyland-Jones, MB BS, PhD, director of Edith Sanford Breast Cancer Research, will present four scientific abstracts highlighting emerging treatments for hard-to-treat cancers, such as triple negative breast cancer, and new insights on biologic targets and prevention. Leyland-Jones will be joined by other members of the research team, including Casey Williams, PhD, clinical director of research; as well as Pradip De, PhD; Nandini Dey, PhD; and Yuliang Sun, MD, PhD. Now in its 36th year, the annual symposium is the foremost gathering of scientists, physicians and health care professionals dedicated to ending breast cancer. It aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer. The details of the Edith Sanford Breast Cancer Research presentations are as follows:  

Thursday, December 12, 2013  
5:00-7:00 PM

Poster Session 3

& Reception

(P3-04-02) Absence of PTEN Facilitates the Anti-tumor Efficacy of GDC-0980 in Combination with ABT888 plus Carboplatin in BRCA1-competent Triple Negative Breast Cancer.Dey N, Sun Y, Carlson J, Friedman L, De P, Leyland-Jones B.

Exhibit Halls A-B

Friday, December 13, 2013  
11:00 AM

General Session 5

(S5-07) SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment.Smerage JB, Barlow WE, Hayes DF, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O’Rourke MA, Lew DL, Gralow JR, Livingston RB, Hortobagyi GN.

Exhibit Hall D

4:15 PM

General Session 6

(S6-05) High levels of APOBEC3B, a DNA deaminase and an enzymatic source of C-to-T transitions, are a validated marker of poor outcome in estrogen receptor-positive breast cancer.Sieuwerts AM, Burns M, Look MP, Meijer-Van Gelder ME, Schlicker A, Heidemann MR, Jacobs H, Wessels L, Willis S, Leyland-Jones B, Gray K, Foekens JA, Harris RS, Martens JW.

Exhibit Hall D

5:00-7:00 PM

Poster Session 5

& Reception

(P5-06-01) The PI3K inhibitor GDC-0941 combines with trastuzumab for superior anti-tumor efficacy in HER2+ breast cancer models.De P, Sun Y, Carlson J, Friedman L, Dey N, Leyland-Jones B.

Exhibit Halls A-B

 

About the Edith Sanford Breast Cancer Foundation

The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations.

About Sanford Health

Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation. It is the largest rural, nonprofit health care system in the nation with locations in 126 communities, in nine states.

 

Edith Sanford Named Official Charity Partner of Women’s Running Series

Foundation will serve as official charity partner for the 2014 Women’s Running Series with inclusion of TeamEdith™ engagement platform at all Women’s Running events (Sioux Falls, S.D.) –The Women's Running Series LogoFoundation will serve as official charity partner for the 2014 Women’s Running Series with inclusion of TeamEdith™ engagement platform at all Women’s Running events
(Sioux Falls, S.D.) –The Edith Sanford Breast Cancer Foundation announced today that it will become the official charity partner for the 2014 Women’s Running Series, beginning with Women’s Running San Diego Half Marathon on February 22, 2014. 
This announcement comes on the heels of the Foundation’s successful debut as charity partner of the recent Women’s Running Scottsdale/Tempe Half Marathon + 5K.
“We are excited to be the official charity of the Women’s Running Series,” said Kimberly Simpson, president of the Edith Sanford Breast Cancer Foundation. “This is an ideal opportunity to help advance our mission to end breast cancer.”
As a result of the partnership, the Foundation will kick off fundraising activities related to the 2014 race series in February at the Women’s Running San Diego Half Marathon. National Edith Sanford spokesperson and former host of Entertainment Tonight, Mary Hart, will participate in the San Diego event in honor of her grandmother, who died from breast cancer, and her mother, who is a breast cancer survivor.
“With its groundbreaking genomics research and commitment to prevention and healthy, active living, the Edith Sanford Breast Cancer Foundation is the perfect partner for the 2014 Women’s Running Series,” said Dana Allen, general manager of the Series. “We are excited to be in a position to assist the Foundation in furthering its mission to accelerate research and end breast cancer for future generations.”
Women’s Running Series participants will be eligible for exclusive benefits and discounts when they register for a Women’s Running event as members of TeamEdith™, the charity’s new participant engagement platform. In addition to receiving a discount off of event registration, athletes will receive TeamEdith-branded athletic wear and other incentives from the Foundation as thanks for supporting their research efforts.
“A healthy, active lifestyle is key in reducing an individual’s risk for breast cancer,” said Gary Hall, Jr., 10-time Olympic medalist and director of sports marketing for the Foundation. “This partnership is a great way to help spread that lifesaving message and bring our TeamEdith platform to a community of strong, dynamic women.”
The Women’s Running Series encompasses four half marathon and 5K events uniquely catered to women, combining a fun destination with scenic courses for the ultimate girls’ weekend getaway. The events are open to both runners and walkers.
For more information on the Women’s Running Series, visit womenshalfmarathon.com or like the event series on Facebook at facebook.com/womenshalfmarathon. To learn more about TeamEdith opportunities or to join a TeamEdith event, visit edithsanford.org/get-involved.
About Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations. Edith Sanford Breast Cancer is pursuing cutting-edge translational genomic research to identify specific treatments that will work best for each person, prevent the disease on an individual basis, and ultimately eradicate breast cancer.
About Women’s Running Series Operated by Competitor Group, the Women’s Running Series (WRS) is the largest women-only half marathon and 5K series in the nation. Four 2014 events in San Diego, Ca. (Feb. 22), Nashville, Tenn. (Sept. 27), Scottsdale-Tempe, Ariz. (Nov. 2), and St. Petersburg, Fla. (Nov. 23), are expected to host more than 15,000 total runners.  The Women’s Running Series awards all half marathon finishers a glitzy two-in-one medal and commemorative charm, post-race treats in the Cookie Café, refreshing bubbly and a rejuvenating Freshen Up Lounge. All events begin with a women-specific Health & Fitness Expotique and finish with an outdoor party complete with food, music and white linen tablecloths.
For more information, please visit womenshalfmarathon.com or facebook.com/womenshalfmarathon.

Edith Sanford Partners With Athena Breast Health Network to Personalize Breast Cancer Risk Assessment

(Sioux Falls, SD and San Francisco, CA) – Edith Sanford Breast Cancer (ESBC), part of the Sanford Health system based in Sioux Falls, SD, today announced it is partnering with the Athena Breast (Sioux Falls, SD and San Francisco, CA) – Edith Sanford Breast Cancer (ESBC), part of the Sanford Health system based in Sioux Falls, SD, today announced it is partnering with the Athena Breast Health Network, a University of California program, to advance the use of a personalized breast cancer risk assessment. The innovative program includes a breast cancer risk assessment tool and a care plan for high-risk patients. Additionally, it will offer patients the opportunity to participate in research aimed at gaining a better understanding of breast cancer and its risk factors, ultimately raising the standard of care for women everywhere. This program marks another milestone in ESBC’s mission to end breast cancer. Athena Breast Health Network is a collaboration among the five University of California medical centers. ESBC is its first partner outside of California and was selected because of its expertise in breast cancer genomics and its ability to integrate the risk assessment into patient care. “This new partnership allows us to use the latest risk assessment technology to uncover a woman’s potential to develop breast cancer and to then to develop customized care plans for her,” said Thomas Cink, MD, a fellowship-trained breast radiologist with Edith Sanford. “A risk factor is anything that increases a person’s chance of developing cancer. Risk factors don’t necessarily mean a woman will develop breast cancer, but understanding them allows a woman and her physician to make more informed health care and lifestyle choices.” As part of the new standard of care, prior to a breast screening (mammogram) appointment, Sanford Health patients will complete an Athena screening questionnaire online at home or in the clinic. Patients identified with an elevated risk will be referred to additional resources and specialists including risk-reduction programs and/or genetic counseling. The risk assessment process evaluation includes the following risk factors for breast cancer: • Age • Personal history of breast cancer • Family history of breast cancer • Genetic predisposition • Personal history of ovarian cancer • Lifestyle (weight, smoking, alcohol use) • Dense breasts • Postmenopausal hormone replacement therapy • Race/ethnicity • Previous radiation exposure • Lobular Carcinoma In Situ (LCIS) • Atypical hyperplasia found in breast biopsy In the near future, Athena will integrate breast density and small variations in inherited gene profiles, or so-called single nucleotide polymorphisms (SNPS) into the standard risk assessment process. The Athena Breast Health Network already has collected patient-reported data on more than 41,000 women and 7,900 biospecimens from women across the state of California. In addition, the network has identified 673 women at elevated risk for breast cancer and completed 466 elevated-risk consultations with breast health specialists. Sanford patients who complete the survey also will be given the opportunity to participate in research to further scientific knowledge on the development of breast cancer. One of the program goals is to engage the support of 4,000 women diagnosed with breast cancer to participate in a study to identify DNA, or genetic, markers. “This milestone collaboration will benefit our patients today and women everywhere tomorrow,” said Brian Leyland-Jones, MB BS, PhD, director of Edith Sanford’s genomic research program. “With the help of those women who volunteer to participate in the study, and through genomic sequencing, we will strive to better understand what drives breast cancer at the molecular level, so we can improve treatment and someday prevent the disease altogether.” “Our goal is to learn who is at risk for what kind of breast cancer and tailor screening and prevention accordingly,” said Laura Esserman, MD, MBA, founding director of Athena and director of the UCSF Breast Care Center. “We welcome the participation of Sanford Health in this exciting practice-changing endeavor.” Sanford Health will begin implementing the Athena screening and risk assessment model in pilot locations in the coming months. Athena will be implemented across the Sanford Health system beginning in 2014. About Sanford Health and Edith Sanford Breast Cancer Sanford Health is the largest rural nonprofit health care system in the nation with locations in 126 communities, in nine states. In addition, this dynamic integrated health system is now developing international clinics in Ghana, Israel and Mexico. Sanford Health has more than 26,000 employees, and includes 39 hospitals, 140 clinic locations and 1,360 physicians in 81 specialty areas of medicine. In 2011, Sanford Health announced the launch of the Edith Sanford Breast Cancer Initiative, a bold new endeavor to end breast cancer, comprised of state-of-the-art patient care, genomic research and national fundraising through the Edith Sanford Breast Cancer Foundation. About Athena Breast Care Network The Athena Breast Health Network (Athena) is a unique collaboration among the five University of California (UC) medical/cancer centers (UC Davis, UC Irvine, UCLA, UC San Diego and UCSF), the Graduate School of Public Health at UC Berkeley, and many other public and private partners. The Network takes a transdisciplinary approach by design, and its participants work together across fields including: epidemiology, genetics, molecular biology, psychology and social and behavioral sciences, primary care, radiology, pathology, oncology, surgery and health services research. Also included are clinical staff and genetic counselors, health information technology professionals, health care administrators, and importantly, patient advocates. Athena is integrating clinical care and research in order to revolutionize the delivery of breast care. By standardizing the collection of data from both patients and physicians, integrating molecular profiling at the time of breast cancer diagnosis, and creating an unparalleled biospecimen repository, Athena will enable personalized care informed by science and will fuel continuous improvement in treatment options and outcomes. Key components of Athena include: • Identifying women at high risk for breast cancer who will be offered prevention services and decision support • A comprehensive informatics strategy that includes tools to collect, analyze, and distribute clinical and research data in real time • Web-based decision tools for patients and providers to translate clinical evidence into actionable treatment options – allowing physicians to tailor treatment to biology, patient preference and clinical performance • A data and biospecimen repository to support large-scale, longitudinal studies that will enable tailored prevention and treatment strategies Underpinning these goals is a culture that supports continuous improvement, as well as a commitment by Athena clinicians and researchers across California to share data. With this unique collaboration, Athena aims to change the options for patients today and create a better future for all women at risk of developing breast cancer. UC Disclaimer The information stated above was prepared by Sanford Health and reflects solely the opinion of the health system. Nothing in this statement shall be construed to imply any support or endorsement of Sanford, or any of its products, by The Regents of the University of California, its officers, agents and employees. Contact: Stacy Bauer Jones | Media Relations Manager | Sioux Falls Region 605.366.2432| stacy.jones@sanfordhealth.org

Edith Sanford Teams up with Women’s Running Scottsdale-Tempe as Official Charity Partner

Foundation to be official charity partner of the November 3 event and introduce new TeamEdith engagement platform (Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation is proud to

Foundation to be official charity partner of the November 3 event and introduce new TeamEdith engagement platform

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation is proud to announce that it will be the official charity partner for the Women’s Running  Series Scottsdale-Tempe Half Marathon + 5K to be held on November 3.  The event weekend will also serve as the first Women’s Running Series event to host Edith Sanford’s TeamEdith™ sports engagement platform. “We are excited to be the official charity of the Women’s Running Scottsdale-Tempe event,” said Kimberly Simpson, president of the Edith Sanford Breast Cancer Foundation. “This partnership is also great way to bring our TeamEdith platform to the active lifestyle community and allows us to align our mission with the passions of health-conscious, active women.” Through the partnership, participants will be eligible for exclusive benefits and discounts when they register for a Women’s Running Series event as members of TeamEdith. In addition to receiving a discount off of the registration fee for Women’s Series events, athletes will receive TeamEdith-branded athletic wear and other premium items as recognition for their efforts in fundraising for the Foundation. “Our races will provide a great platform to help the Edith Sanford Breast Cancer Foundation raise funds and drive their research and mission to end breast cancer for future generations,” said Dana Allen, general manager of the Women’s Running Series. “We look forward to showcasing the nonprofit’s cutting-edge genomic research and its commitment to prevention through the promotion of healthy, active lifestyles. We are thrilled to have a ground-breaking organization like the Foundation as our charity partner for the Women’s Running Series.” The Women’s Running Scottsdale-Tempe Half Marathon + 5K is part of a national series of events uniquely catered toward women, combining a fun destination with scenic courses for the ultimate girls’ weekend getaway. The event, open to both runners and walkers, features exclusive perks such as shiny finisher medals, post-race treats like delicious cookies and refreshing bubbly, and a rejuvenating Freshen Up Lounge. For more information on the Women’s Running Series, visit womenshalfmarathon.com or like the event series on Facebook at facebook.com/womenshalfmarathon. To learn more about TeamEdith opportunities, visit edithsanford.org/get-involved. About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. About Women’s Running Series Operated by Competitor Group, the Women’s Running Series (WRS) is the largest women-only half marathon and 5K series in the nation. Four 2013 events in San Diego, Ca. (Feb. 24), Nashville, Tenn. (Sept. 28), Scottsdale-Tempe, Ariz. (Nov. 3), and St. Petersburg, Fla. (Nov. 24), are expected to host more than 15,000 total runners.  The Women’s Running Series awards all half marathon finishers a glitzy two-in-one medal and commemorative charm, post-race treats in the Cookie Café, refreshing bubbly and a rejuvenating Freshen Up Lounge. All events begin with a women-specific Health & Fitness Expotique and finish with an outdoor party complete with food, music and white linen tablecloths. For more information, please visit womenshalfmarathon.com or facebook.com/womenshalfmarathon.

Edith Sanford and the Minnesota Lynx Go Pink for Breast Cancer

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation and the Minnesota Lynx have partnered for the eighth annual Breast Health Awareness game on Saturday, August 24 as the Lynx face (Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation and the Minnesota Lynx have partnered for the eighth annual Breast Health Awareness game on Saturday, August 24 as the Lynx face off with the Indiana Fever (6 pm tip) in a rematch of last season’s WNBA Finals. The Lynx will be wearing commemorative pink uniforms and auctioning them off to fans after the game. Additionally, Saturday’s game will be a “pink out," with all fans in attendance receiving a free pink t-shirt produced by The Vanity Project. “We are extremely proud of our partnership with the Lynx and grateful for their ongoing support the Foundation’s truly game-changing goal – to end breast cancer through groundbreaking genomic research,” said Kimberly Simpson, president of the Edith Sanford Breast Cancer Foundation. “This is our second year working together on the Breast Health Awareness game, and we look forward to seeing a sea of pink in the arena on Saturday!” Following the game, the entire team will head back out to the court to autograph and auction the game-worn jerseys off their backs and pose for a picture with the auction winners. All proceeds from the night will benefit the Lynx Foundation, which supports breast cancer research and support programs throughout the state of Minnesota. The Breast Health Awareness Week will continue on Thursday, August 29 when Edith Sanford and the Lynx host the fifth annual Catwalk for a Cure. Held from 5 to 8 pm at the Mall of America Rotunda, the Lynx will trade in their high tops for high heels and strut their stuff in a fashion show. The event begins at 5 pm at Sky Deck Sports Grille and Lanes, where attendees will receive free dinner and free bowling, with special appearances by Lynx players. A silent auction, featuring sports memorabilia and unique experiences from around the Twin Cities, will also be held during dinner at Sky Deck Sports Grille and Lanes until 6:30 pm. The fashion show, which will feature the entire Lynx roster and coaching staff, will start in the Mall of America Rotunda at 6:30 pm. All proceeds from the evening will benefit the Lynx Foundation. Saturday's game against the Indiana Fever marks the beginning of Minnesota's Breast Health Awareness Week as part of WNBA's BHA platform. For 15 years, the program has focused on generating awareness and educating women about breast cancer, in addition to raising funds for the initiative. The WNBA, its teams and players are supporting the effort to fight breast cancer during WNBA Breast Health Awareness Week, August 18-24, and have raised more than $2 million to aid in the fight against breast cancer. Tickets are still available for Saturday's game, and the rest of the team’s remaining home schedule, and can be purchased by calling the Lynx at 612.673.8400 or by visiting lynxbasketball.com. Fans interested in attending or looking for more information on the fifth annual Catwalk for a Cure can contact Amanda Collins, Lynx CR manager, at 612.673.1681 or collins@lynxbasketball.com.   About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. Edith Sanford Breast Cancer is pursuing cutting-edge translational genomic research to identify specific treatments that will work best for each person, prevent the disease on an individual basis, and ultimately eradicate breast cancer. The launch of this movement began with a gift from Denny Sanford, who tragically lost his mother, Edith, to breast cancer when he was just four years old. For more information about the Edith Sanford Breast Cancer Foundation, visit edithsanford.org or call 1.855.GO.EDITH (463.3484). About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation, and the largest rural, nonprofit health care system in the nation with locations in 126 communities, in eight states. In addition, this dynamic integrated health system is now developing international clinics in Ghana, Israel and Mexico. Sanford Health has been in service for more than 100 years and includes 35 hospitals, 140 clinic locations and 1,360 physicians in 81 specialty areas of medicine. With more than 26,000 employees, Sanford Health is the largest employer in North and South Dakota.

Edith Sanford and DelMoSports Inc. Team Up for Triathlon Events

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation has partnered with premier event and race organizer DelMoSports Inc. to expand opportunities for athletes to support Edith (Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation has partnered with premier event and race organizer DelMoSports Inc. to expand opportunities for athletes to support Edith Sanford’s cutting-edge genomic research. “We’re thrilled to join forces with DelMoSports in advancing our bold, comprehensive approach to ending breast cancer,” said Kimberly Simpson, president of the Edith Sanford Breast Cancer Foundation. “This partnership opens the door for athletes on the East Coast to support our mission while participating in amazing events.” This year, as a result of the collaboration with Stephen Del Monte, founder and promoter of DelMoSports Inc., athletes will be eligible for exclusive benefits and discounts when they register for DelMoSports triathlons as members of TeamEdith, Edith Sanford’s new athlete engagement platform. Along with receiving 50 percent off the registration fee for prestigious triathlon events, athletes can receive TeamEdith athletic shirts and hooded sweatshirts as a thank-you from Edith Sanford, which they can wear while they train, fundraise and compete. “Stephen has really gone all out to promote TeamEdith and make it easy for athletes to support a great cause while they enjoy these triathlon events,” said Gary Hall, Jr., former Olympian and sports marketing director for the Foundation. “He’s providing a great platform for TeamEdith to thrive and excel, while building momentum for our cause.” Launched earlier this summer, TeamEdith promotes and encourages healthy lifestyles, and gives its team members a variety of opportunities and incentives to raise funds in support of Edith Sanford’s mission. One hundred percent of every dollar raised is invested in advancing breast cancer research. “Edith Sanford puts 100 percent of every dollar toward finding the cures for breast cancer—that makes this partnership a no-brainer for DelMoSports,” said Del Monte. “When TeamEdith participants cross the finish line, they’ll know they’ve also contributed to a lifesaving cause.” Del Monte created DelMoSports Inc. with the goal of having not only elite triathlon races, but also fun and unique events based on the East Coast. These events provide thousands of participants a variety of activities including safe ocean swims, closed bike courses, beach and boardwalk runs, breakfast buffets on the beach, massive prize giveaways, face painting for children, touchscreen results, live entertainment and finisher medals. Partnership events this year include the 10th Annual Tri the Wildwoods Triathlon & 5K in North Wildwood, N.J. on Aug. 17 and the 3rd Annual Atlantic City International and Sprint Distance Triathlons in Atlantic City, N.J. on Sept. 15. Learn more by visiting edithsanford.org/get-involved. About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations. About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation. It is the largest rural, nonprofit health care system in the nation with locations in 126 communities, in eight states.  

Edith Sanford Convenes National Thought Leaders Council

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation is breaking new ground in the nonprofit space by looking to successful entrepreneurs and social innovators to help reach its (Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation is breaking new ground in the nonprofit space by looking to successful entrepreneurs and social innovators to help reach its philanthropic goals. Last week in Sioux Falls, S.D., the Foundation convened the first meeting of its National Thought Leaders Advisory Council, a think tank designed to help formulate fresh new strategies for building grassroots support.

"The Edith Sanford initiative was founded as a catalyst for transformational change in the way we think about and treat breast cancer," said Kimberly Simpson, president of the Edith Sanford Breast Cancer Foundation. "Part of our success depends on going beyond the mainstream and leveraging the experience, connections and insights of creative, entrepreneurial thinkers from a wide variety of professional backgrounds." “Edith Sanford stands out because it embraces innovation in everything from its mission to the way it does business,” said council member Ron McCray, a private investor and corporate director who has also served as chief administrative officer of Nike, Inc. and as chief legal officer of Kimberly-Clark Corporation. “Every for-profit business knows that a culture of creativity and innovation is the key to success, but it’s unique for a charitable nonprofit to be so nimble and forward thinking.” The distinguished council represents recognized leaders in areas including biotechnology, IT, health care, food, consumer goods, apparel, digital media, finance, and political consulting. Each member was carefully selected to ensure a diversity of experience and perspective that the Foundation will draw on to help identify and maximize engagement, grassroots fundraising and major gift philanthropy opportunities. In addition to McCray, the council boasts names such as Jan Fields, former president of McDonald's USA, LLC, who has been named to the Forbes list of “The World’s 100 Most Powerful Women.” "I am very excited about the bold new approach to breast cancer," said Fields. "I think Edith Sanford is the answer to finally ending this devastating disease."
Another leader on the council is Craig Arnold, president and CEO of Permara LLC. Arnold previously served as a director of the Bill and Melinda Gates Foundation, where he led initiatives to bring access to computers and the internet to small towns and large cities in the U.S., Canada, Mexico and Chile. "I believe in Edith Sanford's approach to ending breast cancer and raising the standard of care for women everywhere. I'm eager to contribute to the success of its mission," said Arnold. Edith-group-4                   Members:   Craig Arnold Arnold is the president and chief executive officer of the technology company Permara LLC and a former director of the Bill and Melinda Gates Foundation, where he led one of the foundation’s earliest initiatives to bring access to computers and the internet to small towns and large cities in the United States, Canada, Mexico and Chile. Arnold has also served as chief executive officer at Plymouth Energy and has been a board member for NPower.   Katie Behnke Behnke is managing partner and cofounder of The Starboard Group. She is a successful political and fundraising campaign advisor who has worked with a veritable who’s who of Colorado politics, including U.S. Sen. Ben Nighthorse Campbell and Gov. Bill Owens.   Janice (Jan) Fields Fields is the former president of McDonald's USA, LLC, and one of the most widely recognized women in business leadership. She currently serves on the boards of St. Louis-based Monsanto, The Field Museum, The Global Board of Ronald McDonald House Charities, and chairs the Board of United Cerebral Palsy.  She is also a member of The Chicago Network, an organization of professional women in the upper echelons of business, the arts, government, and academia. Fields has been named to the Forbes list of “The World’s 100 Most Powerful Women,” Fortune’s “50 Most Powerful Women in Business” list, The Wall Street Journal’s “50 Women to Watch” list, and Crain’s Chicago Business list of “25 Women to Watch.”   Ralph Kauten Kauten is the chairman and chief executive officer of Quintessence Biosciences, Inc. located in Madison, Wisc.  Kauten has served as co-founder and leader of a number of biotechnology companies including Promega Corporation, PanVera Corporation, and Mirus Corporation. He has also been designated as an Entrepreneur of the Year by Ernst and Young.   Clare A. Martorana Martorana is a digital media executive who has held senior leadership positions with WebMD Health, including the role of senior vice president of partnerships and editor-at-large at WebMD Health, and the senior vice president and general manager of the WebMD Network. Before joining WebMD, she served as chief operating officer at oncology.com. Martorana's previous experience includes the positions of vice president and executive producer at CBS HealthWatch by Medscape, where she developed CBS HealthWatch radio and broadcast programming as well as special projects for CBS. Martorana has also worked as an independent film producer at SDR Films and Coleman Parker Productions in New York where she produced numerous feature films and documentaries.   Ron McCray McCray is a private investor and corporate director. He previously served as the chief administrative officer of Nike, Inc., and chief legal officer of Kimberly-Clarke Corporation. McCray is the minority owner of the Boston Celtics NBA franchise and serves on the boards of Cornell University and the Harvard Law School. By nomination of President Obama and Senate confirmation, he is also a member of the Federal Retirement Thrift Investment Board.   Pierce H. McDowell III McDowell is a co-founder and current president, co-chairman and co-chief executive officer of South Dakota Trust Company LLC and South Dakota Planning Company LLC. The former is a national trust boutique company for the wealthy based in Sioux Falls, S.D., and the latter a trust/estate planning consulting, marketing and sales firm based in New York City.   Matthew Meskell Meskell works on operations, product and strategy at a privately-held company based in Silicon Valley whose software enables integrating, analyzing, and visualizing large-scale data.  He previously served as a managing director for a multi-billion dollar investment fund dedicated to macro trading strategies. Meskell has also served as a law clerk on the U.S. Court of Appeals for the D.C. Circuit and practiced law with a focus on intellectual property disputes.   Catherine Rodewald Rodewald has served as the president and chief executive officer with Prudential Asset Resources, Inc. and the managing director/chief information officer for Prudential Mortgage Capital Company. Rodewald has also held leadership positions with AMRESCO (international publicly traded diversified financial services corporation) and Ernst and Young (formerly Kenneth Leventhal & Company). She was also formerly president of the Komen affiliate in Dallas.   Dwayne Spradlin Spradlin is the chief executive officer of Health Data Consortium, a Washington, DC-based nonprofit public private partnership advocating and enabling improvements in health and health care through better use of health data. He previously served as president and chief executive officer of InnoCentive, the pioneer in open innovation and crowdsourcing, president of Hoovers Online, president and chief operations officer of StarCite Inc., senior vice president at VerticalNet Inc., and director at PriceWaterhouseCoopers, where he spent ten years delivering technology and strategy solutions to Fortune 500 clients. Spradlin recently coauthored The Open Innovation Marketplace, published by FT Press; and his article “Are You Solving the Right Problem?” was published in the September 2012 issue of Harvard Business Review.   Jan Stadler Stadler is a breast cancer advocate and survivor, community volunteer, and she is actively involved in supporting several nonprofits. Stadler is married to professional golfer Craig Stadler, and helps manage the business side of their busy life in golf.   Carolyn Valentine Valentine is the senior director for global strategic marketing at McNeil Nutritionals, a division of Johnson & Johnson. Prior to joining McNeil, Carolyn was area senior director of commercial and business development for Europe, Middle East, Africa and Pakistan (EMEA), within the International Nutrition Division of Abbott Laboratories.   Karen Williams Williams leads strategic initiatives focused on increasing sales and profitability as executive director of strategic operations implementation for DineEquity, parent of Applebee’s Grill and Bar and IHOP. Before joining DineEquity, Williams acted as an internal consultant to senior management at 7-Eleven, and contributed to more than a four-fold increase in profitability at Corner Bakery Cafe, its sale to a private equity-backed group and its transition to stand alone status. She has held progressive supply chain management positions with PepsiCo and its spin-offs, Yum! Brands and the Unified Foodservice Purchasing Co-op (UFPC), developing and executing supply strategy for Pizza Hut and new concepts such as WingStreet.   Cynthia Hardy Young Young is global head of agency at AIG.  She focuses on consumer and small commercial business written through intermediaries worldwide. She is also the former president of Encompass Insurance, a $2.5-billion division of Allstate Insurance that sells personal lines products countrywide through two brands.     About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations.   About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation. It is the largest rural, nonprofit health care system in the nation with locations in 126 communities, in eight states.   Contact: Stacy Bauer Jones Sanford Health Media Relations 24/7 Media Line: 605.366.2432 stacy.jones@sanfordhealth.org Follow me on Twitter @SanfordStacy

Edith Sanford Research Team Presenting at ASCO Annual Meeting

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation today announced that the Edith Sanford Breast Cancer Research team will share new findings at the 2013 annual meeting of the

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation today announced that the Edith Sanford Breast Cancer Research team will share new findings at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO), which runs May 31 through June 4 in Chicago. Brian Leyland-Jones, MB BS, PhD, director of Edith Sanford Breast Cancer Research, and members of the translational breast cancer research team, will present four scientific abstracts during the meeting, which will attract nearly 30,000 cancer specialists from around the world. Their work will highlight new insights about the treatment of HER2 and triple negative breast cancer, two particularly lethal forms of breast cancer. Leyland-Jones will also be involved in a presentation discussing the results of a long-term assessment of trastuzumab-related cardiac events in women with HER2-positive early breast cancer. ASCO is the world’s leading professional organization representing physicians who care for people with cancer. This year’s meeting, based on the theme Building Bridges to Conquer Cancer, features research that embodies the new era of precision medicine. The details of the Edith Sanford Breast Cancer Research presentations are as follows:   Saturday, June 1, 2013 8:00 AM - 12 PM
  • Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial.

de Azambuja E, Procter M, Muschol M, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith I, Gianni L, Baselga J, Jackish C, Cameron D, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM.

  Monday, June 3, 2013 8:00 – 11:45 AM
  • Prognostic effect of EIF4EBP1 on ovarian cancer: A single gene biomarker for overall survival and platinum response.

Villalobos VM, Wang Y, Willis S, Leyland-Jones B, Sikic BI.

  8:00 – 11:45 AM
  • Frequently deleted genes in ovarian cancer as indicators of platinum response.

Willis S, Villalobos VM, Young B, Sikic BI, Leyland-Jones B.

  8:00 – 11:45 AM
  • A combination of dual PI3K-mTOR inhibitor, GDC-0980, with PARP inhibitor plus carboplatin blocked tumor growth of BRCA-competent triple-negative breast cancer cells.

Dey N, Sun Y, Carlson J, Friedman L, De P.

  Abstracts Accepted for Publication:
  • Pan-PI3K and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistance to trastuzumab therapy.

De P, Sun Y, Friedman L, Dey N, Leyland-Jones B.

 
  • Survival effects of erythropoiesis-stimulating agents (ESAs) in patients with breast cancer: a meta- analysis.

Leyland-Jones B, Aapro M, Möbus V, Nitz U, O’Shaughnessy J, Pronzato P, Untch M, Tomita D, Bohac C.

  
About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations.   About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation. It is the largest rural, nonprofit health care system in the nation with locations in 126 communities, in eight states. ###

Edith Sanford Research Team to Present at AACR Annual Meeting

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation announced today that the Edith Sanford Breast Cancer Research team will share its latest findings at the 2013 annual meeting of the

Edith Sanford Launches National Fundraising Campaign

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation is taking a major step to mobilize support for its bold new approach to eradicate breast cancer. Edith Sanford will engage a broad (Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation is taking a major step to mobilize support for its bold new approach to eradicate breast cancer. Edith Sanford will engage a broad audience through a national Direct Response Television (DRTV) campaign. DRTV is a largely unexplored fundraising strategy for breast cancer research, and it has the added benefit of raising awareness about the importance of research in saving lives. “The television spot is a creative way to tell our story and show why we are so driven to find the cures,” said Kimberly Simpson, president of the Edith Sanford Breast Cancer Foundation. “Most importantly, the Foundation has the distinctive ability to invest 100 percent of every dollar we raise directly into our genomics research initiative to accelerate progress against breast cancer.” The campaign began airing on March 17 and features breast cancer patients and survivors emphasizing the lifesaving importance of research, and their urgent desire for a healthier, breast cancer-free future for themselves, their children and grandchildren. Also prominent in the spots is South Dakota native Mary Hart, the former Entertainment Tonight anchor, who serves as national spokesperson for the Foundation. Hart’s grandmother lost her life to breast cancer and her mother is a survivor. “We are so grateful to Mary for putting her name behind this cause and to each of the exceptional women who were willing to share their experiences with us,” said Simpson. “Their stories, and the stories of thousands of women like them, remind us of the urgency behind Edith Sanford’s quest to end breast cancer.” The research funded by the Edith Sanford Breast Cancer Foundation is leading the way toward a new standard of care that integrates genomics into patient care—using each patient’s unique genetic profile to deliver meaningful treatment options.   About the Edith Sanford Breast Cancer Foundation  The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations.   About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation. It is the largest rural, nonprofit health care system in the nation with locations in 126 communities, in eight states.   Contact:  Stacy Bauer Jones Sanford Health Media Relations 24/7 Media Line: 605.366.2432 stacy.jones@sanfordhealth.org Follow me on Twitter @SanfordStacy

Edith Sanford Researchers to Present at 2012 San Antonio Breast Cancer Symposium

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation today released a schedule detailing research that will be presented by Edith Sanford Breast Cancer Research leaders at the 2012

(Sioux Falls, SD) – The Edith Sanford Breast Cancer Foundation today released a schedule detailing research that will be presented by Edith Sanford Breast Cancer Research leaders at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium this week.

Brian Leyland-Jones, MB BS, PhD, director of Edith Sanford Breast Cancer Research, will present eight scientific abstracts highlighting emerging treatments for hard-to-treat cancers, such as triple negative breast cancer, and new insights on biologic targets and prevention. Leyland-Jones will be joined by Edith Sanford associate scientists Pradip De, PhD and Nandini Dey, PhD, as well as staff scientist Yuliang Sun, MD, PhD. Now in its 35th year, the annual symposium is the foremost gathering of scientists, physicians and health care professionals dedicated to eradicating breast cancer. It aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer. The details of the Edith Sanford Breast Cancer Research presentations are as follows: Thursday, December 6, 2012 4:00 pm                General Session 4      (S4-4) Independent validation of Genomic Grade in the BIG 1-98 study. Sotiriou C, Ignatiadis M, Desmedt C, Veys I, Larsimont D, Viale G, Leyland-Jones B, Kammler R, Ditzel H, Regan MM, Piccart M, Michiels S. 5:00-7:00 pm       Poster Session OT2      (OT2-3-11) Tivozanib in combination with paclitaxel vs placebo in combination with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer. Mayer EL, Miller K, O'Shaughnessy J, Dickler M, Vogel C, Leyland-Jones B, Steelman L, Robinson M, Kuriyama N, Agarwal S. Friday, December 7, 2012 9:45 am                General Session 5     (S5-2) HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvantchemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Goldhirsch A, Piccart-Gebhart MJ, Procter M, de Azambuja E, Weber HA, Untch M, Smith I, Gianni L, Jackisch C, Cameron D, Bell R, Dowsett M, Gelber RD, Leyland-Jones B, Baselga J on behalf of the HERA Study Team. 5:00-7:00 pm       Poster Session OT3     (OT3-4-04) InVite: an observational pilot study evaluating the feasibility of genome-wide association studies using self-reported data from patients with metastatic breast cancer treated with bevacizumab. Faoro L, Barnholt K, Kiefer A, Yager S, Yi J, Turner B, Keane A, Wang L, Eriksson N, Milián M, Leyland-Jones B, O’Neill V. 5:00-7:00 pm       Poster Session 5          (P5-18-02) Selective crossover in randomized trials of adjuvant trastuzumab for breast cancer: Coping with success. Regan MM, Dafni U, Karlis D, Goldhirsch A, Untch M, Smith I, Gianni L, Jackisch C, de Azambuja E, Heinzmann D, Cameron D, Bell R, Dowsett M, Baselga J, Leyland-Jones B, Piccart-Gebhart MJ, Gelber RD.      5:00-7:00 pm       Poster Session 5          (P5-19-03) Olaparib plus carboplatin in combination with vandetanib inhibited the growth of BRCA-wt triple negative breast tumors in mice: Outside BRCA-box.Dey N, Sun Y, De P, Leyland-Jones B. 5:00-7:00 pm       Poster Discussion 10  (PD10-03) Predictive value of a proliferation score (MS) in postmenopausal women with endocrine-responsive breast cancer: Results from International Breast Cancer Study Group (IBCSG) Trial IX. Sninsky J, Wang A, Gray K, Lagier R, Christopherson C, Rowland C, Chang M, Kammler R, Viale G, Kwok S, Regan M, Leyland-Jones B. Saturday, December 8, 2012 7:00-8:30 am       Poster Session 6          (P6-04-11) Combination of PI3K-AKT-mTOR and MEK-ERK pathway inhibitors overcome acquired resistance to letrozole in ER+ breast cancer models.De P, Sun Y, Friedman LS, Chen S, Dey N, Leyland-Jones B.   About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. Edith Sanford Breast Cancer is pursuing cutting-edge translational genomic research to identify specific treatments that will work best for each person, prevent the disease on an individual basis, and ultimately eradicate breast cancer. To accelerate the research and advances in care, a cornerstone of this ground-breaking organization is our biobank – a shared collection of genetic information from people of all ages, medical histories and backgrounds – that provides researchers easy access to data. The launch of this movement began with a gift from Denny Sanford, who tragically lost his mother, Edith, to breast cancer when he was just four years old. For more information about the Edith Sanford Breast Cancer Foundation, visit edithsanford.org or call 1.855.GO.EDITH(463.3484). About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation, and the largest rural, nonprofit health care system in the nation with locations in 126 communities in eight states. In addition, this dynamic integrated health system is now developing international clinics in Ireland, Ghana, Israel and Mexico. Sanford Health has been in service for more than 100 years and includes 35 hospitals, 140 clinic locations and nearly 1200 physicians in 70 specialty areas of medicine. With more than 25,000 employees, Sanford Health is the largest employer in North and South Dakota. Contact: Stacy Bauer Jones Sanford Health Media Relations 24/7 Media Line: 605.366.2432 stacy.jones@sanfordhealth.org Follow me on Twitter @SanfordStacy read more

Edith Sanford Researchers Featured for Triple Negative Breast Cancer Insights

(Sioux Falls, SD) – Researchers affiliated with the Edith Sanford Breast Cancer Research were recently recognized for their insights about a particularly lethal form of breast cancer. In an (Sioux Falls, SD) – Researchers affiliated with the Edith Sanford Breast Cancer Research were recently recognized for their insights about a particularly lethal form of breast cancer. In an article featured on the cover, and highlighted in the November edition of the scientific journal, Current Drug Targets, lead author Nandini Dey, PhD, and Brian Leyland-Jones, MB BS, PhD, director of Edith Sanford Breast Cancer Research, explore the difficulties that have limited effective treatment options for patients with basal-like and triple negative breast cancers. Within this comprehensive analysis, the authors also identify promising opportunities to outsmart the elusive disease. “Triple negative breast cancer is an incorrigible disease that outsmarts all our conventional forms of therapy,” said Dey. “We believe the strategy needs to shift toward using combinations of targeted drugs that hit multiple points in the cancer cell’s internal wiring. It’s unlikely that any single therapy will be adequate on its own.” Triple-negative breast cancer, which accounts for about 12 to 24 percent of all breast cancer cases, is an umbrella term for a group of highly aggressive subtypes that are most common in younger women and African Americans. These subtypes, many of which are also categorized as basal-like, are defined by the absence of receptors for estrogen and progesterone, as well as by the absence of overactive human epidermal growth factor receptors, which drive a majority of breast cancers. The lack of any of these distinct and targetable genetic aberrations is the key reason that basal-like and triple negative breast cancers are so hard to treat. In spite of these challenges, Dey says the outlook is getting brighter. In particular, she points to the use of existing and emerging agents that, when used in the right combinations according to each patient’s individual genetic makeup, have the potential to effectively combat basal-like and triple negative breast cancers. The idea behind this approach is that the drugs will work together to damage a tumor cell’s DNA beyond repair, while simultaneously blocking the cellular pathways it needs to survive, and ultimately force it into apoptosis, or programmed cell death. The research team at Edith Sanford is now looking ahead to validate such novel drug combinations through clinical testing conducted at their facilities. “Our approach will utilize genomic sequencing to identify subpopulations and ensure patients receive the right combination in the right dose for their specific subtype,” explained Leyland-Jones. “Edith Sanford will continue fueling the momentum toward better, smarter and gene-based ways to personalize treatment for all women.” Edith Sanford Breast Cancer Research is supported by the Edith Sanford Breast Cancer Foundation, a national nonprofit organization dedicated to eradicating breast cancer through genomic and translational research. Thanks to a transformational gift that launched the Foundation in 2011 and will catalyze its future growth, Edith Sanford is able to commit 100 percent of every contribution to its research program. About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. Edith Sanford Breast Cancer is pursuing cutting-edge translational genomic research to identify specific treatments that will work best for each person, prevent the disease on an individual basis, and ultimately eradicate breast cancer. To accelerate the research and advances in care, a cornerstone of this ground-breaking organization is our biobank – a shared collection of genetic information from people of all ages, medical histories and backgrounds – that provides researchers easy access to data. The launch of this movement began with a gift from Denny Sanford, who tragically lost his mother, Edith, to breast cancer when he was just four years old. For more information about the Edith Sanford Breast Cancer Foundation, visit edithsanford.org or call 1.855.GO.EDITH (463.3484). About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation, and the largest rural, nonprofit health care system in the nation with locations in 126 communities, in eight states. In addition, this dynamic integrated health system is now developing international clinics in Ireland, Ghana, Israel and Mexico. Sanford Health has been in service for more than 100 years and includes 35 hospitals, 140 clinic locations and nearly 1200 physicians in 70 specialty areas of medicine. With more than 25,000 employees, Sanford Health is the largest employer in North and South Dakota. Contact: Stacy Bauer Jones Sanford Health Media Relations 24/7 Media Line: 605.366.2432  stacy.jones@sanfordhealth.org Follow me on Twitter @SanfordStacy read more

The Edith Sanford Breast Cancer Foundation And The Scripps Research Institute Partner To Advance Genomic Breast Cancer Research

(Sioux Falls, SD, Jupiter, FL, La Jolla, CA) – The Edith Sanford Breast Cancer Foundation and The Scripps Research Institute (TSRI) today announced a dynamic, interdisciplinary collaboration (Sioux Falls, SD, Jupiter, FL, La Jolla, CA) – The Edith Sanford Breast Cancer Foundation and The Scripps Research Institute (TSRI) today announced a dynamic, interdisciplinary collaboration that will lay the groundwork for significant advancements in personalized breast cancer treatment and care. Edith Sanford Breast Cancer Research will leverage TSRI’s expertise in genomic sequencing as it embarks on a proof-of-concept study to reveal the differences between a woman’s normal genome and her breast tumor genome during the progression of disease. The project marks an important milestone for Edith Sanford, as it will establish research protocols to frame larger-scale studies that will help pioneer the integration of genomics into breast cancer research and patient care. “Edith Sanford is thrilled to partner with Scripps Research, an institution that is on the cutting-edge of genomics, and harness their expertise and technological capabilities in our work to accelerate these discoveries from the bench to bedside,” said Brian Leyland Jones, MB BS, PhD, director of Edith Sanford Breast Cancer Research. “This partnership will facilitate the translation of large-scale sequencing data into meaningful information that will help us understand how to more precisely and accurately treat breast cancer patients based on their DNA profiles.” Specifically, Edith Sanford will provide TSRI with tissue samples from 25 breast cancer patients for analysis to identify the changes in genes and proteins that are linked to the cancer and Edith Sanford will then validate these findings through clinical testing. “Scripps Research is committed to helping accelerate the work of Edith Sanford to bring to patients the lifesaving potential of forward genomic research,” said Brandon Young, director of the Genomics and Cell-Based Screening Core Lab at Scripps Florida. “We are excited to work with Edith Sanford as it is establishing a genomics program that will transform the way we think about and treat breast cancer.” Young and colleagues, Nicholas Schork, PhD, Ali Torkamani, PhD, and Andrew Su, PhD, at Scripps California, and the Genomics Core at Scripps Florida will be working jointly with the research team at Edith Sanford. Additionally, in order to mine and accurately interpret vast sets of patient data produced in this field of research, Edith Sanford recently established the foundation for a leading bioinformatics program through the hire of Scooter Willis, PhD, as its director of computational bioinformatics. Dr. Willis is a specialist in computer science and engineering and brings expertise in the genomic analysis of expression data from the fast-moving field of next-generation sequencing. He will also work closely with TSRI and play a vital role in facilitating the partnership. The prestigious partnership with TSRI, which Leland-Jones confirms is the first of many high-caliber collaborations, and the ongoing recruitment of leading scientific experts, are pivotal steps for Edith Sanford Breast Cancer Research as it positions itself as a national hub for breast cancer genomic research. Edith Sanford Breast Cancer Research is supported by the Edith Sanford Breast Cancer Foundation, a national nonprofit organization dedicated to eradicating breast cancer through genomic and translational research. Thanks to a transformational gift that launched the Foundation in 2011 and will catalyze its future growth, Edith Sanford is able to commit 100 percent of every contribution to its research program. “To change the course of breast cancer, our research team is pursuing collaborations to bring together the brightest minds from different scientific fields to quickly move the field of breast cancer research, treatment and care,” said Kimberly Simpson Earle, president of the Edith Sanford Breast Cancer Foundation. About the Edith Sanford Breast Cancer Foundation The Edith Sanford Breast Cancer Foundation is pioneering a bold new comprehensive approach to breast cancer, with a mission to unlock each woman's genetic code, advance today's prevention and treatment, and end breast cancer for future generations. Edith Sanford Breast Cancer is pursuing cutting-edge translational genomic research to identify specific treatments that will work best for each person, prevent the disease on an individual basis, and ultimately eradicate breast cancer. To accelerate the research and advances in care, a cornerstone of this ground-breaking organization is our biobank – a shared collection of genetic information from people of all ages, medical histories and backgrounds – that provides researchers easy access to data. The launch of this movement began with a gift from Denny Sanford, who tragically lost his mother, Edith, to breast cancer when he was just four years old. For more information about the Edith Sanford Breast Cancer Foundation, visit edithsanford.org or call 1.855.GO.EDITH (463.3484). About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation, and the largest rural, nonprofit health care system in the nation with locations in 126 communities, in seven states. In addition, this dynamic integrated health system is now developing international clinics in Ireland, Ghana, Israel and Mexico. Sanford Health has been in service for more than 100 years and includes 35 hospitals, 140 clinic locations and nearly 1200 physicians in 70 specialty areas of medicine. With more than 25,000 employees, Sanford Health is the largest employer in North and South Dakota. About The Scripps Research Institute The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, TSRI has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu. Contact: Stacy Bauer Jones Sanford Health Media Relations 24/7 Media Line: 605.366.2432  stacy.jones@sanfordhealth.org Follow me on Twitter @SanfordStacy Mika Elizabeth Ono The Scripps Research Institute 858.784.2052 mikaono@scripps.edu read more

Brian Leyland-Jones MB BS, PhD to Lead Edith Sanford Breast Cancer Research

(Sioux Falls, SD & Fargo, ND) – After conducting an extensive national search for a physician-scientist to lead Edith Sanford Breast Cancer Research, Sanford Health has hired

(Sioux Falls, SD & Fargo, ND) - After conducting an extensive national search for a physician-scientist to lead Edith Sanford Breast Cancer Research, Sanford Health has hired internationally renowned breast cancer researcher and clinician, Brian Leyland-Jones, MB BS, PhD, to lead this new breast cancer genomic research program and state-of-the-art breast cancer center. Dr. Leyland-Jones is known for his leadership in the development of novel clinical trials and how genomics plays a pivotal part of advancing individualized cancer therapies in the fight against breast cancer. Dr. Leyland-Jones will play a vital role as director of Edith Sanford Breast Cancer Research and also as a senior scientist with Sanford Research. He most recently served as the associate vice president and director of the Emory Winship Cancer Institute. Before joining Emory in November 2006, Dr. Leyland-Jones was the Minda de Gunzberg Chair in Oncology and professor of medicine at McGill University in Montreal, Canada. Dr. Leyland-Jones holds biochemistry, medical and doctoral degrees from the University of London. Following residency training at Hammersmith, Brompton, St. Bartholomew's and London hospitals, he completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. He then joined the academic staff at Memorial Sloan-Kettering Cancer Center and New York Hospitals with a special research interest in early clinical evaluation of new anti-cancer compounds. He has authored more than 150 peer-reviewed articles and book contributions, 200 abstracts and 34 patents. "We live at a pivotal moment in cancer research, when the interface of deep genomic profiling and targeted therapies has the potential of transforming breast cancer,” said Dr. Leyland-Jones. “I am honored to join the outstanding Sanford team, and to leverage Denny Sanford’s extraordinary vision and gift with partners and colleagues around the globe, in utilizing genomic medicine to further both the prevention and cure of this devastating disease." The launch of Edith Sanford Breast Cancer followed a $100 million gift from Denny Sanford to accelerate the research and advances in care for women with breast cancer. “We believe we are at the dawn of a new era in breast cancer treatment and research,” says Kimberly Simpson Earle, president of the Edith Sanford Breast Cancer Foundation. A portion of this gift was used to establish a biobank to support the work of Edith Sanford Breast Cancer Research. The biobank is a repository for genetic information from women of all ages, medical histories and backgrounds. The vision is to create a genetic repository unlike anything available today for all breast cancer researchers in the U.S.  Researchers will use the collected samples to look for changes in DNA that are associated with certain types of breast cancer. “We are so excited to welcome Dr. Leyland-Jones,” said Sanford Research President Eugene Hoyme, MD. “He’s an experienced leader with a national reputation in genomics, a passion for this cause and an extensive background that surpasses most.”  Colleague Kimberly Simpson Earle agrees, “As the Edith Sanford Breast Cancer movement continues to grow nationwide, Dr. Leyland-Jones’ knowledge, prestige and networking will prove an invaluable asset as we speed toward better treatments and ultimately the eradication of breast cancer.” About Sanford Health Sanford Health is the patient care and research partner of the Edith Sanford Breast Cancer Foundation, and the largest rural, not-for-profit health care system in the nation with locations in 112 communities, in seven states. In addition, this dynamic integrated health system is now developing international clinics in Ireland, Ghana, Israel and Mexico. Sanford Health has been in service for more than 100 years and includes 35 hospitals, 140 clinic locations and nearly 1200 physicians in 70 specialty areas of medicine. With more than 25,000 employees, Sanford Health is the largest employer in North and South Dakota. read more

Edith Sanford Breast Cancer Foundation Rounds Out Leadership Team

(Sioux Falls, SD) – Edith Sanford Breast Cancer Foundation is pleased to announce that Chris Dockter has been added to the leadership team as the vice president of philanthropic giving. (Sioux Falls, SD) - Edith Sanford Breast Cancer Foundation is pleased to announce that Chris Dockter has been added to the leadership team as the vice president of philanthropic giving. Edith Sanford Breast Cancer was launched in 2011 to pioneer a bold new comprehensive approach to breast cancer with a mission to unlock each women’s genetic code, advance today’s prevention and treatment, and end breast cancer for future generations. Dockter will develop a highly skilled team that will fuel the visionary goals of the Edith Sanford Breast Cancer Foundation. She and her team will work with a nationwide grassroots network of supporters as well as individuals interested in major and planned gifts to energize the movement. Dockter brings more than twenty years of nonprofit leadership success to the Edith Sanford Breast Cancer Foundation including fundraising experience at university and private schools in California and Oregon. Dockter most recently served as the chief executive officer of the Oregon and SW Washington Affiliate of Susan G. Komen for the Cure, where she was one of the leading representatives of Komen’s Affiliate network. “I am honored to be part of this amazing team,” said Dockter. “As a sister and daughter of breast cancer survivors I understand the personal agony associated with this deadly disease. Supporting Edith Sanford Breast Cancer’s transformational research initiatives provides hope to women and their families affected by the disease.” With the addition of Dockter, the initial leadership team for the Edith Sanford Breast Cancer Foundation is complete. “Chris Dockter’s talent and experience will help us connect donors to their passion for finding the cures for breast cancer,” said Kimberly Simpson Earle, president of the Edith Sanford Breast Cancer Foundation. “We have a great team on board to spread the word about this new and exciting approach to beating breast cancer once and for all.” Dockter received a Bachelor of Arts in English Literature from the University of California, Irvine, has served on various nonprofit boards, and has been a speaker on development and leadership topics. Contact: Jessica Brovold Sanford Health Media Relations – Sioux Falls Region 605.366.2432/ jessica.brovold@sanfordhealth.org Follow me on Twitter @SanfordJessica read more

Foundation Leader Takes On Ambitious Goal

(Sioux Falls, SD) – The new president of the Edith Sanford Breast Cancer Foundation has a history of leading national organizations and an ambitious long-term goal ahead of her: raise $100 read more

Sanford Health Announces Turning Point in Crusade Against Breast Cancer

(Sioux Falls, SD & Fargo ND) – Sanford Health CEO Kelby Krabbenhoft, local entrepreneur and philanthropist Denny Sanford and a host of leaders at Sanford Health announced the launch of read more